Keros Q2 net loss narrows to $30.7M; Board plans $375M capital return to stockholders

Keros Therapeutics, Inc.

2025-Q2 EPS reported $2.86 vs consensus -$1.15 ▲ beat (+347.7%)

Net loss of $30.7M in Q2 2025 improved from $45.3M in Q2 2024, driven by Takeda license revenue.
Cash and cash equivalents $690.2M at June 30, 2025, up from $559.9M at Dec 31, 2024.
Board approved return of $375M excess capital to stockholders; cash runway into H1 2028.
Lead asset KER-065 progressing toward Phase 2 trial in Duchenne muscular dystrophy starting Q1 2026.
R&D expenses $43.5M, G&A $14.5M for Q2 2025; both increased vs year-ago period.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.